Germany MATAO trial for newly diagnosed Ovarian Cancer
MATAO-A clinical phase III trial on the use of letrozole maintenance therapy for newly diagnosed advanced ovarian, fallopian tube or peritoneal cancers.
MATAO- MAintenance Therapy with Aromatase inhibitor in epithelial Ovarian cancer: a randomized double-blinded placebo-controlled multi-center phase III Trial including LOGOS (LOw Grade Ovarian cancer Sub-study) (ENGOT-ov54/Swiss-GO-2)
Are you just diagnosed with or does your patient belong to this group with newly diagnosed ovarian, fallopian tube or peritoneal cancer, and would you or your patient like to participate in this study?
Until the end of January 2023, 251 patients had been recruited and 124 randomized into the trial and with the upcoming opening auf our new in Germany, we more than excited to welcome even more patients in the trial.
The MATAO trial as a whole is supported by peer-reviewed grants and funding from:
Stiftung Fürstlicher Kommerzienrat Guido Feger
Reliable Cancer Therapies (Anticancer Fund)
AGO Studiengruppe e.V
(kindly funds this study by providing the drug and placebo for this study and the transport to the CMO free of charge)